Pharmaceuticals

Aquestive Therapeutic

Aquestive Therapeutic released FY2026 Q1 earnings on May 13 After-Market EST, actual revenue USD 14.45 M (forecast USD 10.9 M), actual EPS USD -0.07 (forecast USD -0.1371)

Aquestive Therapeutic to Release FY2026 Q1 Earnings on May 13 After-Market EST, Forecast Revenue USD 10.9 M, EPS USD -0.1371

Aquestive Therapeutic released FY2025 Q4 earnings on March 4 After-Market EST, actual revenue USD 13.02 M (forecast USD 13.28 M), actual EPS USD -0.2612 (forecast USD -0.1325)

Aquestive Therapeutic released FY2025 annual earnings on March 4 After-Market EST, actual revenue USD 44.55 M (forecast USD 44.81 M), actual EPS USD -0.7835 (forecast USD -0.6437)

Aquestive Therapeutics to Release FY2025 Q4 Earnings on March 4 After-Market EST, Forecast Revenue USD 13.28 M, EPS USD -0.1325

Aquestive Therapeutics released FY2025 9-month earnings on November 5 After-Market EST, actual revenue USD 31.53 M, actual EPS USD -0.5161

Aquestive Therapeutic released FY2025 Q3 earnings on November 5 After-Market EST, actual revenue USD 12.81 M (forecast USD 12.94 M), actual EPS USD -0.14 (forecast USD -0.1325)

Aquestive Therapeutic to Release FY2025 Q3 Earnings on November 5 After-Market (EST), Forecast Revenue USD 12.94 M, EPS USD -0.1325

Aquestive Therapeutics Inc. Obtains New Patents for Anaphylm™

Aquestive Therapeutics Inc Announces FDA Will Not Require an Advisory Committee Meeting to Discuss New Drug Application

Aquestive Therapeutic released FY2025 Q2 earnings on August 11 After-Market EST, actual revenue USD 10 M (forecast USD 11.32 M), actual EPS USD -0.1399 (forecast USD -0.1683)

Aquestive Therapeutic released FY2025 Semi-Annual earnings on August 11 After-Market EST, actual revenue USD 18.72 M, actual EPS USD -0.3744

Aquestive Therapeutic to Release FY2025 Q2 Earnings on August 11 After-Market EST, Forecast Revenue USD 11.32 M, EPS USD -0.1683

Aquestive Therapeutics Inc. Schedules Anaphylm™ Application Meeting with Health Canada

Aquestive Therapeutics to Release Positive Data for Anaphylm™ at CFAAR Summit

FDA Accepts Aquestive Therapeutics New Drug Application for Anaphylm

Aquestive Therapeutics Inc. Elects New Board Members

Oppenheimer Rates Aquestive Therapeutics 'Outperform'

Analysts Forecast AQST to Rise 245% in the Next Year

Aquestive Therapeutic released FY2025 Q1 earnings on May 12 After-Market EST, actual revenue USD 8.72 M (forecast USD 12.23 M), actual EPS USD -0.2401 (forecast USD -0.17)

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

AQST

Oppenheimer analyst Andreas Argyrides has reiterated a Buy rating on Aquestive Therapeutics (AQST) with a price target of $8.00. The analyst consensus for the company is a Strong Buy, with an average price target of $8.75. Argyrides has an average return of 10.3% and a 45.76% success rate on his stock recommendations.

Tip Ranks

Oppenheimer

United Therap

Mannkind

Aquestive Therapeutics (AQST) Receives a Buy from Oppenheimer

LABU

SBIO

Aquestive Therapeutics (NASDAQ:AQST) reported Q1 2026 revenue of $14.4 million, a 66% increase year-over-year, driven by higher license and royalty revenues. The company is on track for a Q3 2026 NDA resubmission for ANAFILM after a Type A meeting with the FDA. They secured a $150 million debt facility to support ANAFILM's launch and are advancing the AQST108 program. Plans include a 75-person sales force for ANAFILM and international regulatory submissions in Canada, the UK, and the EU.

benzinga_article

Proshares Ultra Nasdaq Biotech

Direxion S&P Biotech Bull 3X

ALPS Medical Breakthrough

Invesco Biotechnology & Genome ETF

SPDR S&P Biotech

iShares Biotechnology ETF

VanEck Biotech ETF

First Trust NYSE Arca Biotech Index Fd

Aquestive Therapeutics Q1 2026 Earnings Call: Complete Transcript

POCI

STAA

ARKG

In Wednesday's after-market session, Staar Surgical (STAA) shares surged 15.3% to $33.9 following Q1 earnings, while Precision Optics (POCI) rose 15.21% to $5.3 after its Q3 report. Other gainers included Aquestive Therapeutics (AQST) up 13.55% to $4.69, and Psyence Biomedical (PBM) up 10.27% to $5.69. Conversely, MDxHealth (MDXH) plummeted 49.2% to $0.99 after its Q1 report, and Doximity (DOCS) fell 17.49% to $19.3 following Q4 earnings. Other notable losers included Sunshine Biopharma (SBFM) and DarioHealth (DRIO).

Precision Optics

STAAR Surgical

Psyence Biomedical

iShares US Pharma

iShares Global Healthcare

Health Care Select Sector SPDR

First Trust Nasdaq Lux Digital Health Solutions ETF

iShares US Healthcare Providers

SPDR S&P Health Equip

SPDR S&P Health

Ark Genomic Revolution ETF

Global X HealthTech ETF

VG Health

iShares US Medical Devices

PMV Pharma

Quantum Cyber NV

MDxHealth SA

Doximity

Sunshine Biopharma

DarioHealth

Cuprina

Gelteq

PSYENCE BIOMEDICAL LTD C/WTS 25/01/2029(TO PUR COM)

Mainz Biomed NV

SUNSHINE BIOPHARMA INC C/WTS (TO PUR COM)

12 Health Care Stocks Moving In Wednesday's After-Market Session

Aquestive Therapeutics has secured a new five-year term loan facility of up to $150 million with Oaktree, including a $55 million tranche for refinancing existing debt. The loan is secured by company assets and features interest-only payments until 2031. This funding supports the planned launch of Anaphylm and the AdrenaVerse pipeline. The company also reported first-quarter results, including progress on FDA submissions and expansion of its sales force. Analysts rate AQST stock as a Buy with an $8.00 price target, though concerns about financial performance persist.

Indivior Pharmaceuticals

Hypera S.A.

Aquestive Secures New Oaktree Term Loan to Fund Anaphylm

Aquestive Therapeutics shares are trading higher after the company reported better-than-expected Q1 financial results.

Earnings Watch

Aquestive Therapeutic | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 14.45 M

Aquestive Therapeutics has completed a $150 million debt refinancing with Oaktree Capital Management. The new facility will provide flexibility to fund the potential launch of Anaphylm™, pending FDA approval. The agreement reduces principal debt repayments from $45 million to zero over the next three years and lowers interest rates compared to the previous debt agreement. Oaktree's support underscores its commitment to financing innovative medicines. The refinancing is expected to drive growth for Aquestive as it advances its product pipeline, including Anaphylm™, a treatment for severe allergic reactions.

StockTitan

Aquestive Therapeutics Completes $150 Million Debt Refinancing with Oaktree | AQST Stock News

Aquestive Therapeutic(AQST.US)